News from pharmacyclics, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Dec 22, 2014, 09:00 ET

Pharmacyclics Announces Update on IMBRUVICA® (ibrutinib) Waldenstrom's macroglobulinemia (WM) Submission

 Pharmacyclics, Inc. (NASDAQ: PCYC) announced today that the U.S Food and Drug Administration (FDA) has provided a Prescription Drug User Fee...

Dec 12, 2014, 09:00 ET

Pharmacyclics Named 2014 Outstanding Company by BayBio

 Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that it has been awarded BayBio's 2014 Pantheon DiNA™ Award for Outstanding Company...

Dec 09, 2014, 09:00 ET

IMBRUVICA® (ibrutinib) in Combination with Rituximab Data Shows Positive Benefit-Risk Profile in Hematologic Malignancy

New IMBRUVICA® (ibrutinib) Phase II data announced by Pharmacyclics, Inc. (NASDAQ: PCYC) today demonstrates its potential utility as a...

Dec 09, 2014, 09:00 ET

IMBRUVICA® (ibrutinib) Data Demonstrates Safety and Durability of Response at Two-Year Follow-up in Mantle Cell Lymphoma

 New, 27-month IMBRUVICA® (ibrutinib) median follow-up data announced by Pharmacyclics, Inc. (NASDAQ: PCYC) today support the use of...

Dec 09, 2014, 09:00 ET

Longer Follow-Up IMBRUVICA® (ibrutinib) Treatment Demonstrates Sustained Efficacy in Patients with Difficult-to-Treat Chronic Lymphocytic Leukemia (CLL)

Pharmacyclics, Inc. (NASDAQ: PCYC) today announced new, longer term data in IMBRUVICA® (ibrutinib) patients with relapsed/refractory chronic...

Dec 08, 2014, 21:30 ET

IMBRUVICA® (ibrutinib) Data Demonstrates Safety and Durability of Response at Two-Year Follow-up in Mantle Cell Lymphoma

 New, 27-month IMBRUVICA® (ibrutinib) median follow-up data announced by Pharmacyclics, Inc. (NASDAQ: PCYC) today support the use of...

Dec 08, 2014, 21:02 ET

Longer Follow-Up IMBRUVICA® (ibrutinib) Treatment Demonstrates Sustained Efficacy in Patients with Difficult-to-Treat Chronic Lymphocytic Leukemia (CLL)

Pharmacyclics, Inc. (NASDAQ: PCYC) today announced new, longer term data in IMBRUVICA® (ibrutinib) patients with relapsed/refractory chronic...

Dec 08, 2014, 20:45 ET

IMBRUVICA® (ibrutinib) in Combination with Rituximab Data Shows Positive Benefit-Risk Profile in Hematologic Malignancy

New IMBRUVICA® (ibrutinib) Phase II data announced by Pharmacyclics, Inc. (NASDAQ: PCYC) today demonstrates its potential utility as a...

Dec 06, 2014, 15:01 ET

IMBRUVICA® (ibrutinib) Data Suggests Promise in Multiple Myeloma

New IMBRUVICA® (ibrutinib) Phase II data announced here today by Pharmacyclics, Inc. (NASDAQ: PCYC) during the 56th American Society...

Dec 05, 2014, 09:00 ET

Pharmacyclics Announces Launch of informCLL™ Registry for Chronic Lymphocytic Leukemia (CLL) Patients

Pharmacyclics, Inc. (NASDAQ: PCYC) today announced the launch of informCLL™, a large, observational, prospective registry that will explore...

Dec 04, 2014, 09:00 ET

Pharmacyclics Receives 2014 Society for Medicines Research Award for Drug Discovery for Ibrutinib (IMBRUVICA®)

 Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that it has won the prestigious 2014 Society for Medicines Research Award for Drug...

Dec 01, 2014, 09:00 ET

New IMBRUVICA® (ibrutinib) Application Accepted by European Medicines Agency for Waldenstrom's Macroglobulinemia

 Pharmacyclics, Inc. (NASDAQ: PCYC) today announced the acceptance of a Type II variation application for IMBRUVICA® (ibrutinib) by the...

Nov 06, 2014, 09:09 ET

IMBRUVICA® (ibrutinib) Data to be Presented Across Multiple Histologies, Including in Eight Oral Presentations, at 2014 American Society of Hematology (ASH) Annual Meeting

 Pharmacyclics, Inc. (NASDAQ: PCYC) today announced a broad array of new IMBRUVICA® (ibrutinib) data across multiple histologies will be...

Nov 04, 2014, 16:05 ET

Pharmacyclics Reports Third Quarter 2014 Financial Results and Provides Clinical Program Update

Pharmacyclics, Inc. (the "Company") (NASDAQ: PCYC) today reported financial results for the third quarter and nine months ended September 30, 2014,...

Nov 04, 2014, 14:32 ET

AstraZeneca And Pharmacyclics Enter Clinical Trial Collaboration To Evaluate IMBRUVICA® In Hematologic Cancers

 AstraZeneca and Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that they have entered into a clinical trial collaboration to evaluate...

Nov 04, 2014, 11:00 ET

AstraZeneca And Pharmacyclics Enter Immuno-Oncology Clinical Trial Collaboration With IMBRUVICA® In Solid Tumors

AstraZeneca and Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that they have entered into a clinical trial collaboration to evaluate a novel...

Nov 04, 2014, 08:00 ET

AstraZeneca, Pharmacyclics And Janssen Partner On Immuno-Oncology Combination Trials With IMBRUVICA® For Hematologic Cancers

 AstraZeneca, Pharmacyclics, Inc. and Janssen Research & Development LLC ("Janssen") today announced they have entered into a clinical...

Oct 28, 2014, 18:11 ET

Pharmacyclics Announces Conference Call to Discuss Third Quarter Financial Results

 Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that it will hold a conference call and audio webcast to discuss its financial results for...

Oct 20, 2014, 08:00 ET

Pharmacyclics Files Supplemental New Drug Application for IMBRUVICA® for Waldenstrom's Macroglobulinemia

Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug...

Oct 20, 2014, 07:33 ET

IMBRUVICA™ (ibrutinib) ya está aprobado en Europa para el tratamiento de dos cánceres sanguíneos

 Pharmacyclics Switzerland GmbH, una filial de Pharmacyclics, Inc. (NASDAQ: PCYC), ha anunciado hoy que la Comisión Europea (CE) ha...